ALNY
Price
$446.23
Change
-$3.35 (-0.75%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
58.51B
26 days until earnings call
DNLI
Price
$13.95
Change
+$0.52 (+3.87%)
Updated
Sep 26 closing price
Capitalization
2.04B
33 days until earnings call
Interact to see
Advertisement

ALNY vs DNLI

Header iconALNY vs DNLI Comparison
Open Charts ALNY vs DNLIBanner chart's image
Alnylam Pharmaceuticals
Price$446.23
Change-$3.35 (-0.75%)
Volume$9.16K
Capitalization58.51B
Denali Therapeutics
Price$13.95
Change+$0.52 (+3.87%)
Volume$2.33M
Capitalization2.04B
ALNY vs DNLI Comparison Chart in %
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. DNLI commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and DNLI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ALNY: $446.23 vs. DNLI: $13.95)
Brand notoriety: ALNY and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 20% vs. DNLI: 62%
Market capitalization -- ALNY: $58.93B vs. DNLI: $1.96B
ALNY [@Biotechnology] is valued at $58.93B. DNLI’s [@Biotechnology] market capitalization is $1.96B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • ALNY’s TA Score: 3 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than ALNY.

Price Growth

ALNY (@Biotechnology) experienced а -1.62% price change this week, while DNLI (@Biotechnology) price change was +9.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($58.5B) has a higher market cap than DNLI($2.04B). ALNY YTD gains are higher at: 89.635 vs. DNLI (-31.551). ALNY has higher annual earnings (EBITDA): -170.84M vs. DNLI (-521.52M). ALNY has more cash in the bank: 2.86B vs. DNLI (899M). DNLI has less debt than ALNY: DNLI (46.6M) vs ALNY (1.3B). ALNY has higher revenues than DNLI: ALNY (2.46B) vs DNLI (0).
ALNYDNLIALNY / DNLI
Capitalization58.5B2.04B2,868%
EBITDA-170.84M-521.52M33%
Gain YTD89.635-31.551-284%
P/E RatioN/AN/A-
Revenue2.46B0-
Total Cash2.86B899M318%
Total Debt1.3B46.6M2,783%
FUNDAMENTALS RATINGS
ALNY vs DNLI: Fundamental Ratings
ALNY
DNLI
OUTLOOK RATING
1..100
7972
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
8100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3987
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (93) in the Biotechnology industry is in the same range as ALNY (96). This means that DNLI’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for DNLI (100). This means that ALNY’s stock grew significantly faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as ALNY (100). This means that DNLI’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for DNLI (87). This means that ALNY’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ALNY (100). This means that DNLI’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 19 days ago
77%
Declines
ODDS (%)
Bearish Trend 12 days ago
64%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IJSTX13.72N/A
N/A
VY® JPMorgan Small Cap Core Equity S2
ECTMX17.40N/A
N/A
Eaton Vance Dividend Builder C
MCVRX30.73N/A
N/A
MFS Mid Cap Value R2
BGVIX35.34N/A
N/A
Brandes Global Equity I
CFMSX11.86N/A
N/A
Column Mid Cap Select

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with ARGX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
-0.75%
ARGX - ALNY
52%
Loosely correlated
+0.13%
IONS - ALNY
47%
Loosely correlated
+1.78%
BBIO - ALNY
41%
Loosely correlated
+2.14%
DNLI - ALNY
40%
Loosely correlated
+3.87%
CNTA - ALNY
39%
Loosely correlated
+1.22%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+3.87%
NRIX - DNLI
59%
Loosely correlated
+7.20%
OCUL - DNLI
54%
Loosely correlated
+2.33%
RGNX - DNLI
54%
Loosely correlated
+3.10%
BEAM - DNLI
54%
Loosely correlated
-0.48%
IMVT - DNLI
54%
Loosely correlated
+3.51%
More